Can final-year OI data rescue Ultragenyx’s $245M pipeline gamble on setrusumab?

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is holding its position in a high-stakes rare disease bet after announcing that the Phase 3 Orbit study for UX143 (setrusumab) in osteogenesis imperfecta (OI) will continue to its final analysis without an early stop. The American rare disease drugmaker made the disclosure alongside its partner Mereo BioPharma Group plc (NASDAQ: MREO) on July 9, confirming that interim data did not meet early efficacy thresholds—prompting investor concern and a sharp drop in Ultragenyx’s share price. However, both companies reiterated that the program remains fully on track and that final results across the Orbit and Cosmic trials are expected before year-end.

UX143, a sclerostin-inhibiting monoclonal antibody, is being studied in two Phase 3 trials targeting different pediatric and adolescent age cohorts affected by brittle bone disease. The Orbit study focuses on patients aged 5 to 25 across 11 countries, with clinical fracture rate as the primary endpoint. Meanwhile, the Cosmic trial evaluates setrusumab against intravenous bisphosphonates in children aged 2 to under 7. With no globally approved therapies for OI—a rare genetic disorder characterized by bone fragility, deformities, and mobility loss—Ultragenyx is positioning UX143 as a potentially first-in-class treatment with global relevance.

Despite the absence of an early efficacy win, both studies continue dosing and remain consistent with their original statistical plans. The setback lies more in timing than science. Institutional analysts noted that an early stop for efficacy could have opened the door to accelerated regulatory filings in late 2025. With that window delayed, focus shifts back to year-end data and its ability to justify Ultragenyx’s collaboration terms, which include up to $245 million in milestone payments to Mereo BioPharma and global commercialization outside the EU and UK.

Why didn’t the UX143 trial stop early—and does it signal weaker efficacy or just statistical caution?

Ultragenyx confirmed that the interim review met the safety threshold and that the Data Monitoring Committee advised continuation as planned. But for investors expecting a surprise upside, the lack of an early halt raised concerns that UX143’s efficacy signal—at least at this stage—is not dramatically above placebo. Still, this does not mean the drug is ineffective. Instead, it reflects the conservative statistical threshold (p<0.04) required for early stopping, which often demands strong and unambiguous signals to avoid bias or overinterpretation.

Mereo retains commercial rights in Europe and stands to benefit materially from a successful final analysis. The British rare disease developer previously completed a successful adult Phase 2b trial (ASTEROID), which demonstrated strong dose-dependent effects on bone mass and strength. That dataset helped validate setrusumab’s mechanism of action and de-risked the pediatric expansion. For both parties, the late-stage program has now become a reputational and financial inflection point.

With a market estimated to include 60,000 patients in accessible geographies, the OI segment remains largely untapped from a commercial standpoint. Setrusumab’s status as a fully human antibody and its Breakthrough Therapy and Orphan Drug designations from U.S. and EU regulators give it a potential regulatory advantage. However, the delayed gratification in interim data has forced a reset in investor expectations. Ultragenyx, which had enjoyed a valuation near $4 billion prior to the announcement, saw its stock plunge over 25% the next day, underscoring how tightly investors had tied value to a faster data timeline.

The focus now turns to the strength of the final readouts. If the year-end results show statistically significant reductions in fracture rates, especially with favorable safety signals and functional outcomes, Ultragenyx could quickly recapture lost momentum. For Mereo BioPharma, such an outcome would bolster its royalty and milestone path while potentially attracting licensing interest across its broader rare disease portfolio.